Healthcare / BiotechnologyNasdaqCM
$5.60
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-21.0M · quality 52.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
0/100
F
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$48M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-88.4%
↓Gross Margin
N/A
•Debt/Equity
N/A
•Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2010–2025 · 15 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.86x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-34.8M · FCF $-29.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||||||
| Revenue | — | — | — | — | — | — | — | — | — | — | — | $1758.00 | $40138.00 | $632558.00 | $481842.00 | $1500.00 | — |
| Net Income | $-34.8M | $-34.8M | $-25.5M | $-30.1M | $-27.0M | $-20.6M | $-17.8M | $-17.2M | $-11.4M | $-8.1M | $-6.4M | $-15.8M | $-14.7M | $-10.8M | $-5.1M | $-3.4M | $-1.1M |
| EBITDA | — | — | — | — | $-27.7M | $-20.5M | $-14.6M | $-17.2M | $-11.4M | $-7.5M | $-7.7M | $-12.5M | $-11.7M | $-10.3M | $-4.9M | $-3.4M | — |
| EPS | -4.04 | -4.04 | -3.04 | -0.24 | -0.21 | -0.18 | — | — | — | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | -7431.9% | 100.0% | 21.7% | 86.4% | -6379.3% | — |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | -725746.2% | -30323.0% | -1704.9% | -1052.0% | -228612.7% | — |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | -896491.6% | -36518.8% | -1704.9% | -1054.3% | -229484.5% | — |
| Cash Flow | |||||||||||||||||
| Free Cash Flow | $-29.8M | $-29.8M | $-21.0M | $-21.0M | $-20.8M | $-16.5M | $-11.6M | $-9.1M | $-9.1M | — | — | — | — | — | — | — | — |
| Returns | |||||||||||||||||
| ROE | -88.4% | -88.4% | -35.7% | -33.1% | -22.9% | -14.9% | -65.6% | -131.0% | -129.5% | -117.1% | -205.6% | -421.2% | -154.3% | -101.7% | -98.2% | -220.7% | 127.6% |
| Growth & Yield | |||||||||||||||||
| Revenue Growth | — | — | — | — | — | — | — | — | — | — | — | -95.6% | -93.7% | 31.3% | 32022.8% | — | — |
| EPS Growth | -32.9% | -32.9% | -1166.7% | -14.3% | -16.7% | — | — | — | — | — | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Unavailable: positive start/end prices are required.